Armata Announces Significant Clinical, Regulatory, Manufacturing And Operational Progress Supporting Advancement Of AP-SA02 Toward Planned Phase 3 Superiority Study For Adjunct Treatment Of Complicated Bacteremia

FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting

Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step

Phase 3 superiority study remains on track to initiate in the second half of 2026

LOS ANGELES, July 20, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing and operational progress supporting advancement of AP-SA02, the Company's intravenously administered Staphylococcus aureus ("S. aureus") multi-phage product candidate, toward a planned Phase 3 superiority study for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA").

Recent milestones include submission of the complete Phase 3 protocol and comprehensive responses to all comments received from the U.S. Food and Drug Administration ("FDA") following the Company's End-of-Phase 2 (EOP2) meeting, and completion of key manufacturing activities supporting Phase 3 readiness. Collectively, these milestones support the Company's planned initiation of its pivotal Phase 3 superiority study in the second half of 2026, designed to support a future Biologics License Application ("BLA") for AP-SA02.